Immunocore Holdings plc (Stock Symbol: IMCR)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Annual Revenue: $356 million
.
Market Capitalization: $1659 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Immunocore Holdings plc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Immunocore Holdings plc strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Immunocore Holdings plc Stock Price Chart and Technical Analysis
Loading chart data...
Loading Immunocore Holdings plc interactive price chart and technical analysis...
Deep dive into Immunocore Holdings plc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Immunocore Holdings plc stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Immunocore Holdings plc:
P/B Ratio4.27x
Market Cap$1659M
EPS$-0.41
Book Value/Share$7.71
Revenue/Share$7.07
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Immunocore Holdings plc converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Immunocore Holdings plc:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Immunocore Holdings plc's ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Immunocore Holdings plc:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Immunocore Holdings plc's ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Immunocore Holdings plc:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Immunocore Holdings plc uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Immunocore Holdings plc:
Understanding Financial Statement Data
What these metrics mean: Key figures from Immunocore Holdings plc's income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Immunocore Holdings plc: With annual revenue of $356M, Immunocore Holdings plc demonstrates solid business size.
Income Statement ($ Millions)
Total Revenue$356M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding50M
Immunocore Holdings plc (IMCR) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Immunocore Holdings plc stock analysis.
Loading fundamental data...
Loading Immunocore Holdings plc comprehensive fundamental analysis and insider trading data...
Immunocore Holdings plc to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 February 19, 2025 — 07:12 am EST Written by None for Quiver Quantitative -> ...
We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other ...
Immunocore Holdings plc (NASDAQ:IMCR) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for IMCR is 53.1.
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the ...
Q2 2025 Earnings Call Transcript August 9, 2025 Operator: Greetings, and welcome to the Immunocore conference call and webcast. [Operator Instructions] As a reminder, this conference is being recorded ...
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the ...
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune ...
The big shareholder groups in Immunocore Holdings plc (NASDAQ:IMCR) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders ...
Immunocore Holdings PLC Sponsored ADR will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.01, up 100.83% from the prior-year quarter.
Comparative analysis of Immunocore Holdings plc against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
How accurate are Immunocore Holdings plc stock predictions?
Our AI model demonstrates 74% historical accuracy for IMCR predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Immunocore Holdings plc stock price forecasts?
Is Immunocore Holdings plc a good investment in 2025?
Based on our AI analysis, Immunocore Holdings plc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Immunocore Holdings plc forecasts updated?
Immunocore Holdings plc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Immunocore Holdings plc Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Immunocore Holdings plc stock.
